{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:13:04Z","timestamp":1791267184676,"version":"4.1.0"},"reference-count":0,"publisher":"Portico","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1358\/dot.2022.58.11.3448291","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T11:14:32Z","timestamp":1667992472000},"page":"547-552","source":"Crossref","is-referenced-by-count":6,"title":["Current treatment options for treating OPA1-mutant dominant optic\n                        atrophy"],"prefix":"10.3730","volume":"58","author":[{"given":"Lorenzo","family":"Ferro Desideri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Enrico","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Iester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1320","container-title":["Drugs of Today"],"original-title":[],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T19:03:44Z","timestamp":1705691024000},"score":1,"resource":{"primary":{"URL":"http:\/\/access.portico.org\/stable?au=pjb98s6rv72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1358\/dot.2022.58.11.3448291","relation":{},"ISSN":["1699-3993","1699-4019"],"issn-type":[{"value":"1699-3993","type":"print"},{"value":"1699-4019","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}